Table 1 Patients characteristics

Patients demography

 Female

13

3

7

 Male

12

5

4

 Age (years)^*#

60.3 (30–77; ± 11)

60.5 (38–75; ± 11.9)

62.8 (50–77; ± 7)

Characteristics of joints and rifaximin intake

 THA

18

5

9

 TKA

7

3

2

 Rifaximin intake

8

8

/

 Duration of rifaximin intake (months)^*#

/

24.75 (4–60; ± 18)

/

Characteristics of liver cirrhosis in patients

 Cirrhosis underlying disease

 Alcoholic cirrhosis

14

4

8

  Viral hepatitis

5

2

2

Drug toxicity

1

1

/

  Post-ischemic/mof

1

/

1

Unknown origin

2

1

1

  NAFLD

2

/

1

 MELD^*#

13.4 (6–36; ± 6.6)

11.9 (8–18; ± 3)

16.6 (10–36; ± 8.1)

 Child Pugh

 A

16

4

8

  B

7

4

1

  C

2

/

2

 Survival after 6 months

14/25

5/8

6/11